Australian Pharma Industry “Astonished” By Call To Cut Patent-Term Extensions
This article was originally published in PharmAsia News
Executive Summary
A government draft report stuns the industry by calling for restrictions on patent-term extensions as a battle heats up on how to control costs under Australia’s Pharmaceutical Benefits Scheme.